JP2013523886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523886A5 JP2013523886A5 JP2013505048A JP2013505048A JP2013523886A5 JP 2013523886 A5 JP2013523886 A5 JP 2013523886A5 JP 2013505048 A JP2013505048 A JP 2013505048A JP 2013505048 A JP2013505048 A JP 2013505048A JP 2013523886 A5 JP2013523886 A5 JP 2013523886A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- disease antigen
- disease
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 17
- 210000000447 Th1 cell Anatomy 0.000 claims 16
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 5
- 210000003289 regulatory T cell Anatomy 0.000 claims 5
- 230000000735 allogeneic effect Effects 0.000 claims 4
- 230000006058 immune tolerance Effects 0.000 claims 3
- 108010006519 Molecular Chaperones Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102000005431 Molecular Chaperones Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 210000002602 induced regulatory T cell Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 210000002501 natural regulatory T cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32355710P | 2010-04-13 | 2010-04-13 | |
| US61/323,557 | 2010-04-13 | ||
| PCT/US2011/032090 WO2011130249A2 (en) | 2010-04-13 | 2011-04-12 | Methods and compositions for inhibition of treg cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016078393A Division JP2016155851A (ja) | 2010-04-13 | 2016-04-08 | 制御性ｔ細胞の阻害のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523886A JP2013523886A (ja) | 2013-06-17 |
| JP2013523886A5 true JP2013523886A5 (enExample) | 2014-05-15 |
| JP6294666B2 JP6294666B2 (ja) | 2018-03-14 |
Family
ID=44761077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505048A Active JP6294666B2 (ja) | 2010-04-13 | 2011-04-12 | 制御性ｔ細胞の阻害のための方法および組成物 |
| JP2016078393A Pending JP2016155851A (ja) | 2010-04-13 | 2016-04-08 | 制御性ｔ細胞の阻害のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016078393A Pending JP2016155851A (ja) | 2010-04-13 | 2016-04-08 | 制御性ｔ細胞の阻害のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20110250173A1 (enExample) |
| EP (1) | EP2558123B1 (enExample) |
| JP (2) | JP6294666B2 (enExample) |
| KR (3) | KR102117350B1 (enExample) |
| CN (1) | CN103002915B (enExample) |
| AU (3) | AU2011240752B2 (enExample) |
| BR (1) | BR112012026007A2 (enExample) |
| CA (1) | CA2796053A1 (enExample) |
| IL (2) | IL275017B2 (enExample) |
| PH (1) | PH12012502233A1 (enExample) |
| SG (2) | SG184819A1 (enExample) |
| WO (1) | WO2011130249A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102117350B1 (ko) * | 2010-04-13 | 2020-06-02 | 이뮤노베이티브 테라피스, 엘티디. | 조절 t 세포들의 저해를 위한 방법 및 조성물 |
| EP3091990B1 (en) | 2014-01-08 | 2021-05-12 | Mirror Biologics, Inc. | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome |
| TWI714529B (zh) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療 |
| EP3400074B1 (en) * | 2016-01-07 | 2021-10-20 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Compositions for generating immunotolerant responses |
| CN110177558B (zh) * | 2016-09-16 | 2025-02-28 | 贝勒医学院 | 用于病毒特异性t细胞的活化和扩增的平台 |
| KR102507852B1 (ko) * | 2020-01-10 | 2023-03-09 | 이뮤노바이옴 주식회사 | 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도 |
| GB202007321D0 (en) * | 2020-05-18 | 2020-07-01 | Inst De Medicina Molecular Joaeo Lobo Antunes | T cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
| US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
| EE200100203A (et) * | 1998-10-05 | 2002-10-15 | M & E Biotech A/S | Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon |
| US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US6875849B2 (en) | 2001-05-01 | 2005-04-05 | Arizona Board Of Regents Of Behalf Of The University Of Arizona | Methods of recovering chaperone proteins and complexes thereof |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| JPWO2003028758A1 (ja) * | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US20080267964A1 (en) * | 2005-02-17 | 2008-10-30 | Masaki Terabe | Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors |
| KR20080090413A (ko) * | 2005-12-08 | 2008-10-08 | 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 | Ｔ 조절 세포의 확장을 위한 방법 및 조성물 |
| JP5254952B2 (ja) * | 2006-04-13 | 2013-08-07 | イミュノバティブ セラピーズ， リミテッド | 日和見感染症の治療のための同種異系細胞治療 |
| US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| WO2008126940A1 (ja) * | 2007-04-10 | 2008-10-23 | The University Of Tokyo | 新規ｔ細胞 |
| US9695397B2 (en) * | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| EP2141245A1 (en) * | 2008-07-03 | 2010-01-06 | Ivana Türbachova | DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3 |
| KR102117350B1 (ko) * | 2010-04-13 | 2020-06-02 | 이뮤노베이티브 테라피스, 엘티디. | 조절 t 세포들의 저해를 위한 방법 및 조성물 |
| US10479975B2 (en) * | 2014-06-06 | 2019-11-19 | Bluebird Bio, Inc. | Methods of making T cell compositions |
-
2011
- 2011-04-12 KR KR1020187032175A patent/KR102117350B1/ko active Active
- 2011-04-12 IL IL275017A patent/IL275017B2/en unknown
- 2011-04-12 SG SG2012075461A patent/SG184819A1/en unknown
- 2011-04-12 US US13/084,900 patent/US20110250173A1/en not_active Abandoned
- 2011-04-12 KR KR1020127028850A patent/KR20130060188A/ko not_active Ceased
- 2011-04-12 CN CN201180019282.4A patent/CN103002915B/zh active Active
- 2011-04-12 PH PH1/2012/502233A patent/PH12012502233A1/en unknown
- 2011-04-12 BR BR112012026007A patent/BR112012026007A2/pt not_active Application Discontinuation
- 2011-04-12 EP EP11769425.7A patent/EP2558123B1/en active Active
- 2011-04-12 CA CA2796053A patent/CA2796053A1/en active Pending
- 2011-04-12 SG SG10201509539UA patent/SG10201509539UA/en unknown
- 2011-04-12 KR KR1020207014991A patent/KR20200063262A/ko not_active Ceased
- 2011-04-12 AU AU2011240752A patent/AU2011240752B2/en active Active
- 2011-04-12 JP JP2013505048A patent/JP6294666B2/ja active Active
- 2011-04-12 WO PCT/US2011/032090 patent/WO2011130249A2/en not_active Ceased
-
2012
- 2012-10-10 IL IL222343A patent/IL222343B/en active IP Right Grant
-
2016
- 2016-04-08 JP JP2016078393A patent/JP2016155851A/ja active Pending
- 2016-08-24 US US15/245,845 patent/US20160361404A1/en active Pending
- 2016-09-26 AU AU2016231642A patent/AU2016231642B2/en active Active
-
2018
- 2018-07-03 AU AU2018204834A patent/AU2018204834B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523886A5 (enExample) | ||
| NZ630790A (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| MY171356A (en) | Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| WO2013088148A3 (en) | Method of treatment employing therapeutic t cell product from mobilised donors | |
| JP2013541010A5 (enExample) | ||
| MY201732A (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof | |
| JP2014513722A5 (enExample) | ||
| GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| EP2593115A4 (en) | Treatment of t-cell mediated immune disorders | |
| UA112747C2 (uk) | Лікарський засіб і спосіб профілактики інфікування віл, профілактики і лікування захворювань, що викликаються віл або асоційовані з віл, у тому числі сніду | |
| PH12015502844B1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| PH12012502233A1 (en) | Methods and compositions for inhibition of treg cells | |
| SG10201901391RA (en) | Induction of il-12 using immunotherapy | |
| RU2012127158A (ru) | Способ терапии ремиттирующего рассеянного склероза | |
| Kato et al. | Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells | |
| RU2008129232A (ru) | Способ лечения туберкулеза легких у больных вич-инфекцией | |
| Vermeij et al. | Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer, a single arm phase II study | |
| TH135822A (th) | วิธีการและองค์ประกอบสำหรับการยับยั้ง Treg เซลล์ (Treg CELLS) | |
| WO2005044999A3 (en) | Treatment with immunoregulatory t cells | |
| Nakauchi et al. | Novel Therapeutic Approach To Graft-Versus-Host Disease With Allele-Specific Anti-HLA Monoclonal Antibody | |
| Moazzami et al. | Influenza Infection in the Elderly | |
| McDaid et al. | Bespoke Immunosuppression: Targeting Alloreactive T-Cells Using c-FLIP siRNA Prolongs Allograft Survival.: Abstract# D2757 |